What Governance Questions Should We Answer Before Using Behavioural Monitoring?

In an era where digital interactions permeate healthcare, behavioural monitoring is emerging as a powerful approach to identify risks early and tailor interventions. From patient portals to remote monitoring systems, understanding user behaviour promises improved safety, engagement, and outcomes. Yet, as organisations like MrQ and research bodies such as the National Institutes of Health (NIH) explore behavioural signals in regulated environments, governance questions must be front and center to balance innovation with privacy, fairness, and efficacy.

Why Governance Matters in Behavioural Monitoring

Behavioural risk often develops gradually through subtle patterns rather than isolated events. For example, a patient slowly disengaging from a digital health tool poses a different clinical concern than a one-time missed login. Similarly, MrQ—a gambling platform known for leveraging behavioural metrics—illustrates how regulated industries use patterns as early warnings to prevent harm.

Health systems adopting behavioural monitoring must address governance issues including:

• AI Governance: How are algorithms interpreting behavioural data? Are decisions human-reviewed?
• Data Retention: What data is stored, for how long, and who controls it?
• Human Review: When and how should human oversight intervene in AI-flagged risks?

Without careful governance, digital monitoring risks repeating past errors like privacy hand-waving or treating correlation as causation. The goal is to craft oversight frameworks that promote trust, transparency, and patient safety.

Understanding Behavioural Risk: Patterns Over Single Events

Digital footprints in patient portals and remote monitoring systems generate enormous behavioural data streams. But a single event, such as a missed appointment, says little alone. Instead, risk correlates with accumulating patterns — declining login frequency, irregular data entries, or inconsistent physiological readings.

The National Institutes of Health (NIH) research indicates that longitudinal analysis of these behavioural signals can flag emerging risks such as medication non-adherence or mental health deterioration. In this context, governance must address:

1. Signal vs Story: How do we differentiate raw data ("signals") from human interpretations ("stories")? For example, a drop in portal use could mean access issues or improvement in health.
2. Contextualisation: How does the system contextualise data across diverse populations? Behavioural norms can vary widely with demographics and health conditions.
3. False Positives/Negatives: What error rates are acceptable, and what are the impacts of misclassification?

Governance frameworks must ensure evaluation metrics reflect real-world complexity and barrynames avoid simplistic assumptions that certain behaviours always indicate risk.

Learning from Regulated Platforms: Early Warnings through Behavioural Signals

MrQ provides a leading example of regulated behavioural monitoring. As a licensed gambling operator, it uses machine learning models to detect risky playing patterns long before consumer harm escalates. This early warning can trigger tailored support calls or limits.

Health systems looking to adopt similar techniques should consider:

• Regulatory Compliance: What legal frameworks govern behavioural data collection and intervention?
• Transparency: Are patients or users adequately informed about monitoring, data use, and the possibility of interventions?
• Intervention Protocols: What human-in-the-loop procedures ensure AI-generated warnings lead to ethical, supportive actions and not punishment?

These lessons underline the precedence of privacy and evidence standards over technological capabilities. Monitoring for monitoring’s sake can erode trust and create harm.

Privacy and Evidence Standards Must Lead Governance

Privacy is often the most contentious governance question when employing behavioural monitoring. It’s not enough to legalistically comply with data protection laws; organisations must proactively respect user autonomy and confidentiality.

Key governance questions include:

Governance Question Considerations What data is collected and retained? Only data necessary to identify meaningful behavioural risk, minimising invasive data collection How long is data stored? Retention periods must align with clinical relevance and patient rights to data deletion Who can access the data? Strict role-based access controls and audit trails to prevent misuse How is consent obtained? Clear, informed, and ongoing consent, avoiding vague privacy hand-waving What evidence supports use of behavioural signals? Robust validation studies showing predictive accuracy and impact on patient outcomes

The National Institutes of Health (NIH) underscores the need for transparent evidence on what behavioural indicators validly represent health risk before widescale deployment. Ensuring that monitoring does not produce unnecessary anxiety or stigma is crucial.

AI Governance and Human Review: Avoiding Automation Pitfalls

AI-driven behavioural monitoring offers powerful insights but also risks automation bias: over-reliance on algorithms without adequate human oversight. Governance must define clear policies on:

• Algorithm Transparency: How do we audit and explain AI outputs in understandable language to clinicians and patients?
• Human-in-the-Loop Processes: What triggers human review, and how are AI flags triaged to avoid alert fatigue or neglect?
• Training and Bias Mitigation: How are models trained on representative data to avoid perpetuating health disparities?
• Escalation Paths: How are concerning behavioural patterns escalated to appropriate clinicians or care teams?

Without embedding these protections, AI governance risks mirror mistakes of "shipping AI features without a human review path," potentially causing harm instead of alleviating it.

Case Study: Integrating Behavioural Monitoring in a Patient Portal

Consider a remote monitoring system linked to a patient portal designed to track medication adherence and symptom reporting for chronic disease management. Effective governance might look like this:

1. Informed Consent: Patients consent specifically to behavioural monitoring with clear explanations of data use and retention.
2. Minimal Data Collection: Only login frequency, message response times, and self-report consistency are collected—not extraneous personal data.
3. Pattern Analysis: Algorithms identify gradual disengagement patterns rather than isolated missed inputs, flagging patients for outreach.
4. Human Review: Clinical staff review flagged cases before any intervention to understand context and avoid misinterpretation.
5. Privacy Controls: Patients can view and request deletion of their behavioural data within retention limits.
6. Evaluation: Outcomes tracked to assess if monitoring improves adherence without increasing patient anxiety or workload.

This balanced approach draws on experiences from NIH studies and MrQ’s regulated behavioural monitoring, highlighting a governance framework emphasizing transparency, human judgement, and respect for privacy.

Summary: Essential Governance Questions Before Deployment

Governance Domain Key Questions Data Collection & Retention

• What data is necessary and proportionate?
• How long will data be retained?
• Who controls data access?

Privacy & Consent

• Is consent informed, documented, and revocable?
• Are privacy protections strong and transparent?

AI Governance

• Are AI models transparent and explainable?
• How is bias assessed and mitigated?
• What triggers human review of AI outputs?

Clinical Integration

• How do flagged behavioural risks fit into clinical workflows?
• What training supports clinicians interpreting data?

Evidence & Evaluation

• What evidence underpins behavioural signal validity?
• How will outcomes and unintended effects be measured?

Conclusion

Behavioural monitoring in healthcare holds remarkable promise but requires rigorous governance to unlock its benefits responsibly. Drawing insights from regulated platforms like MrQ and research by the National Institutes of Health (NIH), leaders must prioritize privacy, human review, and evidence-driven approaches.

Before deploying AI-powered behavioural monitoring on patient portals or remote monitoring systems, stakeholders must ask hard questions about data retention, AI transparency, and human oversight. Doing so will help avoid the pitfalls of rushed implementation and instead support patient safety, dignity, and trust in digital health innovation.